Cells can be microencapsulated in synthetic hydrogel microspheres (microgels) using droplet microfluidics, but microfluidic devices with a single droplet generating geometry have limited throughput, especially as microgel diameter decreases. Here we demonstrate microencapsulation of human mesenchymal stem cells (hMSCs) in small (<100 μm diameter) microgels utilizing parallel droplet generators on a two-layer elastomer device, which has 600% increased throughput vs. single-nozzle devices. Distribution of microgel diameters were compared between products of parallel vs. single-nozzle configurations for two square nozzle widths, 35 and 100 μm. Microgels produced on parallel nozzles were equivalent to those produced on single nozzles, with substantially the same polydispersity. Microencapsulation of hMSCs was compared for parallel nozzle devices of each width. Thirty five micrometer wide nozzle devices could be operated at twice the cell concentration of 100 μm wide nozzle devices but produced more empty microgels than predicted by a Poisson distribution. Hundred micrometer wide nozzle devices produced microgels as predicted by a Poisson distribution. Polydispersity of microgels did not increase with the addition of cells for either nozzle width. hMSCs encapsulated on 35 μm wide nozzle devices had reduced viability (~70%) and a corresponding decrease in vascular endothelial growth factor (VEGF) secretion compared to hMSCs cultured on tissue culture (TC) plastic. Encapsulating hMSCs using 100 μm wide nozzle devices mitigated loss of viability and function, as measured by VEGF secretion.
Delivery of encapsulated proteins and cells in hydrogel microspheres, or microgels, has emerged as a promising therapeutic strategy for the treatment of various diseases1. Synthetic polymers provide tuneable release rates of encapsulated proteins that can be tailored based on diffusion through the hydrogel network or hydrolytic/enzymatic degradation of microgels2,
Encapsulation of cells in microgels provides several key benefits in transplantation settings. By controlling mesh size of microgels, immune infiltration of transplanted cells can be mitigated while transport of oxygen and cellular waste products is maintained. Because potential sources of therapeutic cells are often allogeneic or xenogeneic, immunoisolation has been extensively investigated for reducing systemic immunosuppression requirements after transplantation5,6. Microgels can also function to immobilize cells at a desired transplant site by entrapping them in gels, an important consideration since many cell therapies currently rely on systemic administration of cells7. In addition to isolating transplanted cells from the host, synthetic microgels permit engineering of encapsulated cell microenvironment, including matrix stiffness and adhesive ligand interactions, which influence differentiation and secretory function of encapsulated stem cells8,9. Bulk hydrogel constructs can provide these benefits as well, but the microgel form factor enables applications for which bulk gels are not well suited, such as injection. In addition, thick polymer coatings are a barrier to nutrients and oxygen, so hypoxic death is frequently observed in bulk gels, and even in large microgels, especially when high cell concentrations are used10. Therefore, microgel size should be minimized in order to maximize transport of oxygen to encapsulated cells and to enable novel, minimally invasive transplantation schemes. Encapsulation of cells in microgels with diameters <100 μm enables immobilization of cells in small blood vessels, including arterioles and larger capillaries. Alternatively, larger microgels may occlude larger vessels, restricting blood flow, and unencapsulated cells are difficult to localize7.
Alginate has been extensively explored for cell microencapsulation because rapid crosslinking allows for facile gelation in cationic aqueous solutions11. However, only limited control of cellular microenvironment is possible with alginate. We have previously developed a microfluidic droplet strategy for generating size-controlled crosslinked synthetic microgels based on 4-arm polyethylene glycol (PEG-4MAL) macromers, which are terminated with maleimides12. Maleimides efficiently react with free thiols to form covalent bonds, allowing any cysteine containing peptide or thiolated ligand to be tethered to microgels. This versatile chemistry enables local and sustained presentation of bioactive molecules in microgels, as well as enzyme-mediated active release of therapeutic proteins when microgels are crosslinked with protease-sensitive crosslinks2. Crosslinking PEG-4MAL macromers can be accomplished with dithiol molecules and does not require free radical initiators, which are detrimental to encapsulated cell health13. Similar microfluidic schemes for producing microgels14,
Minimization of microgel diameter maximizes transport of oxygen and nutrients to encapsulated cells, enables applications for which larger microgels are not suited (such as injection) and potentially reduces transplant graft volume. Microfluidics provide precise control of size and polydispersity of droplets23 and can be used to make very small cell laden microgels, including those with membranes as thin as 6 μm24. Unfortunately, volumetric throughput of macromer on flow focusing nozzles decreases with the cube of droplet diameter, so volumetric throughput can be severely limited when very small microgels are being produced. Furthermore, cells suspended at high concentrations (>106 cells per mL) tend to aggregate, which can lead to incomplete cell encapsulation as well as increased microgel diameters. Therefore, low concentration cell suspensions (104–105 cells per mL) are typically used, often resulting in a high percentage of empty microgels according to the Poisson distribution25, which is undesirable for in vivo efficacy and limits applications of encapsulation. Microgels containing cells can be purified by sorting or can be selectively crosslinked7,24,26,27, but encapsulating clinically relevant numbers of cells in these very small microgels is highly challenging, since several tens of millions of cells may be required for therapeutic efficacy28,29. Long processing times associated with encapsulation or sorting are likely to decrease cell viability, so faster cell microencapsulation rates are desirable not just for convenience, but also to maintain cell potency.
To maximize cell encapsulation rate, both the concentration of cells in suspension and the volumetric throughput of macromer in microfluidic devices must be maximized. One way to increase flow rate of macromer in a microfluidic droplet generating device is to utilize a parallel flow focusing nozzle configuration. However, coupled inlet and outlet flow paths present significant challenges to maintaining size control and low polydispersity of droplet diameter, due to propagation of pressure fluctuations between nozzles. Nonetheless, uniform droplet production has been shown on parallel droplet generators with a variety of configurations30,
Here we report a process for the high-throughput encapsulation of cells in sub-100 μm diameter microgels, which utilizes a novel two-layer microfluidic device with six parallel flow focusing nozzles. Devices with two different nozzle widths, 35 and 100 μm, were developed, each with benefits and disadvantages. Thirty five micrometer wide nozzle devices produce smaller microgels and can break up droplets from precursors with twice the cell concentration as 100 μm wide nozzle devices. However, encapsulation on 35 μm wide nozzle devices reduces viability of human mesenchymal stem cells (hMSCs), and reduces their ability to secrete vascular endothelial growth factor (VEGF) in proportion to this loss of viability. On the other hand, following encapsulation on 100 μm wide nozzle devices, hMSCs have >90% viability and only minimal reduction of VEGF secretion vs. hMSCs cultured on tissue culture (TC) plastic. Although only six parallel channels are utilized in order to maintain robust operation, this parallelization of 100 μm wide nozzles could reduce total encapsulation time by sixfold compared to a single-nozzle device. Microgels with sub-100 μm diameters are ideal for many applications, due to their relatively low polymer content, but encapsulating clinically relevant numbers of cells in small microgels poses unique challenges. The scheme presented here addresses these challenges in a practical but novel way, through simultaneously maximizing cell concentration and effectively parallelizing encapsulation on flow focusing nozzles.
Materials and methods
Photolithography was used to pattern microfluidic masters after spin coating SU-8 2050 photoresist (MicroChem, Westborough, MA, USA) onto silicon wafers, then masters were developed and treated with vapor phase trichloro(1H,1H,2H,2H-perfluorooctyl)silane (Sigma, St. Louis, MO, USA) to reduce sticking. Devices with 35 and 100 μm wide nozzles had focusing layer patterns that were 35 and 100 μm tall, respectively, and their corresponding top layer patterns were 80 and 140 μm tall. PDMS (Sylgard 184) was mixed according to manufacturer specifications and was molded on the SU-8 master to make microfluidic channel replicas (Figure 1a). After curing for 11 min at 110 °C, crosslinker inlet and outlet holes were punched in the top layer, and inter-layer vias were punched in the bottom layer. Relevant surfaces were exposed to air plasma for 20 s in a PlasmaPreen (North Brunswick, NJ, USA) system, and layers were aligned and pressed together by hand before being cured at 110 °C for 5 min. After PDMS to PDMS bond was stabilized, oil and macromer inlets were punched through both layers. These elastomer constructs were sonicated, along with glass substrates, in 200 proof ethanol, and then were dried with compressed nitrogen. Cleaned components were quickly treated with 12 s of plasma and PDMS was bonded to a glass slide, sealing the lower layer flow channels. Devices were cured overnight at 60 °C before being used.
Microgel synthesis and characterization
Microfluidic devices were primed with light mineral oil (Sigma) containing 2% SPAN80 (Sigma), which was also used as the continuous phase fluid. The crosslinker emulsion was comprised of 30 mg mL−1 dithiothreitol (DTT; Sigma) emulsified at a 1:15 ratio in the continuous phase. The macromer solution consisted of 6.5% (w/v) PEG-4MAL (20 kDa, Laysan Bio, Arab, AL, USA), which had been reacted with a cell adhesive peptide (1.0 mM, Genscript, Piscataway, NJ, USA) that was pre-conjugated to AlexaFluor594 (Thermo Fisher, Waltham, MA, USA) to enable imaging and for consistency with cell encapsulation experiments. Also motivated by consistency with subsequent cell encapsulation experiments, this reaction was performed in a buffer which had additives to address challenges associated with cell encapsulation. Particularly, the buffer contained OptiPrep density gradient (Sigma) and PBS in a 1:4 ratio to match the density of cells and minimize settling of cells. The buffer also contained 0.1% Pluronic F108, which reduces cell sticking to glass or PDMS. After connecting the outlet and all inlets, fluid flows were driven at the flow rates prescribed in Table 1 by Hamilton gastight syringes on Harvard Apparatus Elite syringe pumps. To prevent unwanted gelation of polymer precursor on chip and minimize polydispersity due to transient flows, first oil, then crosslinker fluid flows were initiated and allowed to stabilize. Only after flows stabilized was macromer precursor flow initiated. After at least 20 min of generation, microgels were collected in phosphate buffered saline containing 2% bovine serum albumin (to reduce microgel sticking). Most of the oil was removed by aspiration after centrifugation (600 g for 5 min), after which microgels were washed three more times by centrifugation in a new 15 mL conical tube to remove any mineral oil residue from microgels. Microgels were imaged using a Nikon Ti-E microscope with C2-Plus Confocal System, and diameter was determined using ‘Analyze Particles’ on binarized images in ImageJ. Output of three independent microgel generations were characterized for all four device designs tested, with a minimum of 163 microgels counted per device.
Human MSC microencapsulation and characterization
A similar protocol was used to encapsulate hMSCs, with a few modifications. First, hMSCs were trypsinized for 10 min in 0.25% trypsin/EDTA, which minimized cell clumping and homogenized cell morphology compared to shorter trypsinization times. A macromer solution was made containing twice the desired final concentrations—that is, 13 wt% PEG-4MAL, 2.0 mM RGD, 0.2% Pluronic F108, in a buffer comprised of 1:2 OptiPrep in PBS. This precursor was mixed with an equal volume of cells suspended at twice their desired concentration. The resulting solution contained gel precursor concentrations consistent with those used for microgel synthesis and contained the desired concentration of cells in suspension (2×107 cells per mL for 35 μm wide nozzle or 107 cells per mL for 100 μm wide nozzle). This suspension was mixed thoroughly by pipetting and was used as quickly as possible to generate microgels in parallel nozzle microfluidic devices, using the same protocol described for empty microgels. Three independent encapsulations were performed on both the 35 and 100 μm wide nozzles for at least 20 min each, and the resulting microgels were washed with culture media four times by centrifugation. Live and dead cells were then stained with Calcein-AM and TOTO-3 iodide, respectively (Thermo Fisher). Microgels containing cells were imaged on a confocal microscope and were measured in ImageJ. The number of cells per microgel was determined by manual counting due to cell clustering. At least 425 microgels were characterized from each encapsulation.
Human MSC viability in culture
Viability of microencapsulated hMSC was monitored over time for cells encapsulated on parallel microfluidic devices with both 35 and 100 μm wide nozzles. Cell viability on day 0 was calculated by dividing the number of Calcein-AM positive cells by the total number of cells counted. Some encapsulated cells were not stained on day 0 and were instead cultured with media changes every three days. On days 1, 3 and 7 post encapsulation, encapsulated cells were removed from culture and were stained and imaged to determine cell viability. As a control, viability was also determined over time for hMSCs grown on TC plastic. Day 0 viability of cells in microgels was compared for cells encapsulated on 35 μm vs 100 μm wide nozzle devices using Mann–Whitney test in GraphPad (La Jolla, CA, USA).
Twenty four hours following encapsulation, ~105 hMSCs, microencapsulated using either 35 μm or 100 μm nozzle devices, were suspended in 1.0 mL growth media in a 24-well plate. Unencapsulated hMSCs were also seeded onto a 24-well plate at an equal concentration. After incubation for 48 h, conditioned media from all samples was collected and frozen at −80 °C. At the time of analysis, conditioned media was thawed and concentrations of VEGF were quantified using ELISA (Biolegend, San Diego, CA, USA). DNA was quantified from each sample using CyQUANT assay following the manufacturer’s instructions (Thermo Fisher). VEGF secretion was normalized to DNA content, and normalized values were compared between groups using ANOVA with a Tukey post hoc test. P<0.05 was considered significant.
Results and discussion
Microfluidic design and fabrication
Our target application during device development was intravascular cell delivery for extended local VEGF secretion and mitigation of inflammation. Therefore, the goals of our iterative design were to maximize encapsulation throughput as well as viability and function of encapsulated cells while simultaneously minimizing microgel size as well as the number of empty microgels. During the course of preliminary experiments with devices comprised of single square flow focusing nozzles, nozzle widths smaller than 30 μm did not consistently encapsulate cells, especially hMSCs, which were relatively large cells with heterogeneous morphology. Therefore, 35 μm wide nozzles were determined to be the smallest nozzle appropriate for encapsulation of hMSCs. Also during these preliminary experiments, we observed that cell viability was reduced in these very small microgels, which might limit their potency. Cells encapsulated on 100 μm wide nozzles had higher viability, and therefore therapeutic potential, but encapsulation of clinically relevant cell numbers was still challenging. For example, encapsulation of 30 million cells would require ~30 h.
Therefore, we determined that parallel flow focusing geometries and very high cell suspension concentrations were essential for encapsulating clinically relevant cell numbers in a practical time frame. Several different two-layer parallel nozzle flow focusing microfluidic devices were designed and fabricated (for both 35 and 100 μm widths) using soft lithography, in an iterative design process. However, at high cell loading (>5×106 per mL), all devices tested which had more than six channels produced extremely heterogeneous microgel sizes due to increased clogging of nozzles with cells. On the six-nozzle device, clogs with deformable particles frequently cleared themselves due to increasing local pressure; however, on devices with more than six nozzles, sustained clogs were frequently observed, likely because there were channels with lower resistance through which flow could be diverted. These nozzle obstructions would cause oil to divert upstream into the aqueous phase distribution, which perturbed droplet production at multiple nozzles. On the final design (Figure 1), all flow channels on the top layer are relatively large and open (80 μm tall for devices with 35 μm wide nozzles; 140 μm tall for devices with 100 μm wide nozzles), to reduce the pressure stressing the PDMS to PDMS bond. The six nozzle designs represent a compromise achieved through extensive trial and error to balance (a) high cell loading, (b) low empty microgel rate and (c) high cell throughput.
Maximum flow rates of macromer phase resulting in consistent microencapsulation and low polydispersity were determined in previous experiments utilizing mineral oil as the continuous phase. Fluorinated oils produce lower capillary number flow relative to mineral oil, and so can be operated with higher macromer phase flow rates while maintaining dripping flow. We attempted to increase throughput even further by utilizing one such oil, Fluorinert FC40, along with a nonionic fluorinated surfactant purchased from RAN biotechnologies (008) (Beverly, MA, USA). Unfortunately, nozzle-to-nozzle variability in droplet breakup was much greater with fluorinated oils than with mineral oil when utilizing parallel flow focusing nozzle geometries, resulting in more polydispersed droplet diameters. Because of this increased variability and difficulty of maintaining crosslinker emulsion in fluorinated oils, mineral oil was used as the continuous phase for all subsequent experiments.
Parallel encapsulation allows for 600% increased throughput while maintaining size control of microgels
A major benefit of synthesizing microgels with droplet microfluidics is the ability to precisely control microgel size and polydispersity. However, maintaining low polydispersity is challenging in parallel nozzle devices, because any variation in fluidic resistance between flow focusers (or respective distribution/collection channels) results in variation of droplet size produced at each nozzle. We synthesized PEG-4MAL microgels on both single- and parallel nozzle devices in order to characterize any increase in polydispersity due to parallel synthesis (Figure 2). Parallel nozzle devices were operated with six times the flow rate of single-nozzle devices (Table 1). Three separate synthesis runs were performed on three separate devices of each design. Representative histograms of microgel size are shown for each synthesis run (Figures 2a and b) along with representative fluorescent images of microgels. Although Kruskal-Wallis tests indicate differences in median microgel size across devices of the same design (P<0.05 for all four devices), this is likely due to the small variances and large sample sizes. No gross differences in size distribution were seen between microgels generated on multiple devices of the same design (Figure 2), and mean microgel size was highly consistent between devices of the same design (Table 2). For practical purposes, we conclude that microgel production is repeatable on all four microfluidic designs. Microgels analyzed from all three encapsulations were pooled for each device so that comparisons could be made between single and parallel devices with the same nozzle size. For the 35 μm wide nozzle device, a t-test revealed statistical differences (P=0.012; Figure 2c) in mean diameter of microgels produced on parallel vs. single nozzles, but the magnitude of this difference was small (<1.8%)—average diameter was 65.1±8.2 μm for parallel nozzle devices vs. 64.0±6.3 μm for single-nozzle devices (Table 2). The mean diameter was equivalent for pooled microgels produced on 100 μm nozzles (104.5 μm), whether single or parallel configurations were used, and no differences in mean diameter were found (P=0.97). F-tests revealed differences in variance of microgel diameter for parallel vs. single-nozzle production for both nozzle widths tested (P<0.0001 in each case). For 35 μm nozzle width, the parallel configuration resulted in higher standard deviations than the single configuration, as expected. Surprisingly, the single 100 μm nozzle produced microgel diameters with higher standard deviations (±9.6 μm) than those produced on the parallel configuration (±7.5 μm). Whereas statistically significant differences were found between diameters of microgels produced on single vs. parallel nozzle configurations, the differences are small and are unlikely to matter for practical applications. Taken together, these results demonstrate that our parallel microfluidic device is capable of increasing microgel production rate by 600%, while having minimal impact on the size or polydispersity of resulting microgels.
Human MSCs can be encapsulated on parallel nozzle microfluidic device with high loading density
The design criteria of maximum cell throughput and the desire for reduced transplant graft volume and microgel size both motivate a minimization of empty microgels and a maximization of cell loading in each microgel. Increasing the cell concentration in macromer solution exacerbates several challenges that may prevent successful encapsulation. High concentrations of hMSCs tend to aggregate in solution, which often result in many empty microgels and a relatively few, large microgels that contain clusters of cells. The tendency of hMSCs to aggregate was reduced by increasing trypsin exposure from 5 min to 10 min while harvesting cells, without notable deleterious effects on cell viability. Cells, especially when aggregating, tended to stick in microfluidic channels, forming sieves that prevent successful encapsulation. The addition of 0.1% Pluronic F108 eliminated this problem, along with further reducing cell aggregation. Cells also tended to settle in microfluidic tubing because their density is higher than a 6.5% PEG-4MAL solution in PBS, which results in increased cell aggregation and many empty microgels. After adding the cytocompatible density gradient media OptiPrep at a 1:4 ratio in cell suspensions, encapsulation runs up to 30 min were completed without noticeable cell settling. These three process improvements enabled microencapsulation of hMSCs with relatively high loading densities, as shown by fluorescent images in Figure 3a. In these images, green indicates live cells (stained with Calcein-AM), red indicates dead cells (stained with TOTO-3 iodide) and blue indicates the outline of microgels (obtained using ‘Find Edges’ in ImageJ). Histograms showing the frequency of microgels containing a given number of cells are shown in Figure 3b, along with the frequencies predicted by a Poisson distribution, using the measured average value as the expected value. Measured frequencies for number of cells per microgel closely matched those predicted by a Poisson distribution for microencapsulation on both 35 and 100 μm wide nozzles, except that approximately two times more empty microgels are produced than expected on 35 μm wide nozzles. Fewer empty microgels are produced when 100 μm wide nozzles are used rather than 35 μm wide nozzles (P=0.02, Figure 3c), which may lead to more uniform cell spacing in packed microgel arrays.
The diameters of microgels that encapsulate hMSCs were measured from three separate parallel microfluidic devices for both 35 and 100 μm nozzle widths (Table 2). Cell-laden microgels produced on 100 μm wide nozzles had significantly smaller diameter than cell-free microgels, with a modest decrease in mean diameter of 6.4 μm, or 6.1%. Microgels produced on 35 μm wide nozzles were significantly larger when they contained cells than when no cells were present (P<0.0001), with an increase in mean diameter of 11.4 μm, or 18%. Whereas aggregation of cells could explain the larger size of microgels produced on 35 μm wide nozzles, increased polydispersity would be expected if this was the case. Surprisingly, the addition of cells decreased microgel polydispersity when compared to microgels with no cells, as seen by the lower coefficient of variation on 35 μm wide nozzles when cells were present. The presence of cells did not meaningfully impact polydispersity of microgels from 100 μm wide nozzles, although the F-test shows statistically significant differences in variance between cell-laden and cell-free microgels (P<0.0001 for both nozzle sizes; data in Table 2).
Microgels support hMSC viability and VEGF secretion, but the microencapsulation process reduces cell viability in a nozzle size–dependent fashion
Human MSCs were encapsulated in microgels utilizing three separate devices in independent encapsulations, for both 35 and 100 μm nozzle widths with parallel configurations. These microgels were functionalized with a peptide that contained the cell adhesive sequence RGD to support adhesive signaling of encapsulated cells. On days 0, 1, 3 and 7 after encapsulation, live and dead cells were labeled with Calcein-AM and TOTO-3 iodide, respectively, before being imaged, and viable cell fractions were calculated as the fraction of live cells over the total number of cells counted for each sample (Figure 4a). Cells encapsulated on 100 μm wide nozzles had excellent initial viability of <90% on the day of encapsulation, and viability remained high (<75%) on day 3 post encapsulation, indicating that microgels support cell health. In contrast, cells encapsulated on 35 μm wide nozzles average only 71% viability on the day of encapsulation, implicating the smaller dimensions of the device as damaging to cells. This damage could be due to increased probability of cells being exposed to membrane-disrupting mineral oil during encapsulation, which has been shown to decrease encapsulated cell viability39.
To further elucidate the effects of encapsulation on hMSCs, secretion of VEGF was measured 48 h after encapsulation, and was compared with secretion from hMSCs on TC plastic. Secretion of VEGF, which is known to promote angiogenesis40, was reduced in a nozzle size–dependent manner consistent with viability after encapsulation (Figure 4b). This result suggests that the ability of encapsulated cells to secrete VEGF is not negatively impacted, since reduction of VEGF secretion is explained by reduction in viability.
Parallel nozzle microfluidic devices enable encapsulation of clinically relevant numbers of hMSC within practical time constraints
Maintaining cell viability during long encapsulation or sorting processes is challenging, so processing time needs to be minimized. Clinical human and preclinical large animal studies indicate that tens of million cells will likely be required for efficacy of some cell therapies28,29. The parallelized device discussed herein increases throughput by 600% without reductions in cell viability or VEGF secretion. This reduction overcomes a practical limitation of synthetic microgel encapsulation by allowing clinically relevant cell doses to be encapsulated within a standard workday.
Synthetic hydrogels used to deliver cells in vivo can be engineered to provide important biochemical signals to encapsulated cells and host tissue, and tuneable pore size allows for immuno-isolation of encapsulated cells from host tissue. Bulk hydrogel constructs limit mass transport around encapsulated cells and are often prohibitively large when many cells are required. Microencapsulation, or the encapsulation of cells in microgels, can reduce mass transport limitations and large graft sizes associated with bulk encapsulation of cells and enables injectable delivery of cells within controlled microenvironments. All of these benefits are enhanced as microgel diameter is decreased, but volumetric throughput decreases with the cube of nozzle width, so it can be difficult to encapsulate clinically relevant numbers of cells in very small microgels. The parallel microfluidic device presented here increases microgel throughput six-fold with minimal change in polydispersity while maintaining high cell viability and secretory functions. Microencapsulation on 35 μm wide nozzle devices can be done at very high cell loading (2×107 cells per mL), which results in relatively small microgels (76.5±6.6 μm), minimizing graft volume and transport limitations. The lower cell densities required to maintain uniform droplet breakup on 100 μm wide nozzles would result in increased graft volumes, but associated increases in cell viability and throughput may outweigh these concerns. Secretion of VEGF is reduced by hMSC encapsulation proportionally to the nozzle size–dependent loss of viability, which indicates that viable cells maintain capacity to promote angiogenesis. Each nozzle width has been designed prioritizing differently the particular challenges associated with high-throughput cell encapsulation in small microgels, but both of these devices utilize similar, novel approaches to solve limited cell throughput. By using high concentration cell suspensions and parallel flow focusing nozzles, clinically relevant cell numbers can be rapidly encapsulated in small microgels.
This work was funded by NIH (Grant No. R21EB020107) and the Juvenile Diabetes Research Foundation (Grant No. 2-SRA-2014-287-Q-R).
About this article
Trends in Food Science & Technology (2019)